1,609 results on '"Suzuki, Fumitaka"'
Search Results
202. Long-term histological impact of sodium-glucose co-transporter-2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus: 3 cases evaluated by liver histology at 3 years after the start of treatment
203. Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
204. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer
205. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy
206. New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma
207. Treatment of patients with resistant mutants against nucleos(t)ide analogs: Plenary Session 5: Treatment (Resistant Mutants against NA)
208. 18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib
209. Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD
210. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
211. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)
212. Virus Clearance Reduces Bone Fracture in Postmenopausal Women With Osteoporosis and Chronic Liver Disease Caused by Hepatitis C Virus
213. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment
214. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants
215. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan
216. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan
217. Influence of Amino-Acid Polymorphism in the Core Protein on Progression of Liver Disease in Patients Infected With Hepatitis C Virus Genotype 1b
218. Failure to respond to interferon-α 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C
219. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks
220. Losartan Reduces the Onset of Type 2 Diabetes in Hypertensive Japanese Patients With Chronic Hepatitis C
221. Amino Acid Substitutions in the Hepatitis C Virus Core Region of Genotype 1b Are the Important Predictor of Severe Insulin Resistance in Patients Without Cirrhosis and Diabetes Mellitus
222. Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma
223. Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia
224. Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin
225. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?
226. A Matched Case-Controlled Study of 48 and 72 Weeks of Peginterferon Plus Ribavirin Combination Therapy in Patients Infected With HCV Genotype 1b in Japan: Amino Acid Substitutions in HCV Core Region as Predictor of Sustained Virological Response
227. A case of well-differentiated cholangiolocellular carcinoma visualized with contrast-enhanced ultrasonography using Sonazoid
228. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma
229. Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage.
230. Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.
231. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis
232. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: Randomized controlled trial in Japanese patients
233. Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses
234. Efficacy of Low-Dose Intermittent Interferon-Alpha Monotherapy in Patients Infected With Hepatitis C Virus Genotype 1b Who Were Predicted or Failed to Respond to Pegylated Interferon Plus Ribavirin Combination Therapy
235. Substitution of Amino Acid 70 in the Hepatitis C Virus Core Region of Genotype 1b Is an Important Predictor of Elevated Alpha-Fetoprotein in Patients Without Hepatocellular Carcinoma
236. Prolonged-Efficacy of Bisphosphonate in Postmenopausal Women With Osteoporosis and Chronic Liver Disease
237. New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle
238. Changes in viral loads of lamivudine-resistant mutants during entecavir therapy
239. Successful Treatment of an Entecavir-Resistant Hepatitis B Virus Variant
240. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis
241. Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load
242. Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2
243. Interferon-Induced Prolonged Biochemical Response Reduces Hepatocarcinogenesis in Hepatitis C Virus Infection
244. Loss of Hepatitis B Surface Antigen From the Serum of Patients With Chronic Hepatitis Treated With Lamivudine
245. Comparison of Interferon and Lamivudine Treatment in Japanese Patients With HBeAg Positive Chronic Hepatitis B
246. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy
247. Prolonged-Interferon Therapy Reduces Hepatocarcinogenesis in Aged-Patients With Chronic Hepatitis C
248. Interferon and lamivudine monotherapy on chronic hepatitis B in Japan
249. Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report
250. Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma – direct ablative effects and a long-term outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.